Day: March 25, 2026

Koné project construction on-budget and ahead of schedule • Strong continued exploration focus • Robust liquidity sources CONSTRUCTION ACTIVITIESRapid progress achieved with +9.0 million hours worked to date, with more than 3,000 employees and contractors on-site Well on track for first gold pour in late Q4-2026 through the oxide circuit and on budget with $572.8 million of capital committed as at today, representing approximately 65% of the total upfront capital expenditure Key process plant achievements include completion of all CIL tanks and ball mill shell installation, oxide sizer completion, foundation concrete pours for pre-leach and tailings thickeners, and advancement of the hard-rock comminution circuit Other key infrastructure is well advanced including the full operation of the river abstraction and water storage facilities,...

– FDA Grants IND Clearance for SER-252– SER-252 Phase 1b Trial Initiated– Closed Private Placement Financing of up to $30 Million HUNTSVILLE, March 25, 2026 (GLOBE NEWSWIRE) — Serina Therapeutics, Inc. (“Serina” or the “Company”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today reported its financial results for the full year ended December 31, 2025 and provided recent business highlights. “This past year was defined by execution, advancing SER-252 from IND filing through FDA clearance, into the clinic while strengthening our balance sheet to support the clinical milestones ahead,” said Steve Ledger, CEO of Serina. “With the first patient dosed in our registrational trial in advanced Parkinson’s...